Genetic screening for LRRK2 gene G2019S mutation in Parkinson's disease patients from Southern Italy
- PMID: 18621566
- DOI: 10.1016/j.parkreldis.2008.05.011
Genetic screening for LRRK2 gene G2019S mutation in Parkinson's disease patients from Southern Italy
Abstract
Leuchine-rich repeat kinase 2 (LRRK2) gene mutations are a common cause of familial and sporadic Parkinson disease (PD). G2019S is the most frequent mutation of the LRRK2 gene and has been reported in about 5-6% of familial and 1-2% of sporadic PD cases. The aim of this study is to investigate the G2019S frequency in a series of 58 familial and 70 sporadic PD patients recruited from Campania, a region in Southern Italy. We identified one heterozygous G2019S mutation in a PD patient who also suffered from obsessive disorder and depression and presented hallucinations and delusional jealousy while he was treated with l-dopa, pramipexole, and amantadine. Brain (18)F-deoxy-glucose PET showed relative decrease of glucose metabolism in the caudate nuclei and to a lesser extent in cortical parietal/frontal regions. The patient's mother also had PD and molecular analysis demonstrated that she carried the same mutation. G2019S mutation frequency is rather low in overall patients (0.8%) and in the familial group (1.7%), suggesting that it may be an uncommon cause of PD in Southern Italy.
Similar articles
-
The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.J Neural Transm (Vienna). 2009 Nov;116(11):1473-82. doi: 10.1007/s00702-009-0303-0. J Neural Transm (Vienna). 2009. PMID: 19756366 Review.
-
Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.Parkinsonism Relat Disord. 2009 May;15(4):277-80. doi: 10.1016/j.parkreldis.2008.06.009. Epub 2008 Sep 20. Parkinsonism Relat Disord. 2009. PMID: 18805725
-
LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.Arch Neurol. 2006 Mar;63(3):377-82. doi: 10.1001/archneur.63.3.377. Arch Neurol. 2006. PMID: 16533964
-
Genetic screening for the LRRK2 R1441C and G2019S mutations in Parkinsonian patients from Campania.J Parkinsons Dis. 2014;4(1):123-8. doi: 10.3233/JPD-130312. J Parkinsons Dis. 2014. PMID: 24496098
-
LRRK2 G2019S in the North African population: a review.Eur Neurol. 2010;63(6):321-5. doi: 10.1159/000279653. Epub 2010 Apr 23. Eur Neurol. 2010. PMID: 20413974 Review.
Cited by
-
The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.J Neural Transm (Vienna). 2009 Nov;116(11):1473-82. doi: 10.1007/s00702-009-0303-0. J Neural Transm (Vienna). 2009. PMID: 19756366 Review.
-
Genetic Testing in Parkinson's Disease.Mov Disord. 2023 Aug;38(8):1384-1396. doi: 10.1002/mds.29500. Epub 2023 Jun 27. Mov Disord. 2023. PMID: 37365908 Free PMC article.
-
Clinical expression of LRRK2 G2019S mutations in the elderly.Mov Disord. 2010 Nov 15;25(15):2571-6. doi: 10.1002/mds.23330. Mov Disord. 2010. PMID: 20721910 Free PMC article.
-
Principal Component Analysis versus Subject's Residual Profile Analysis for Neuroinflammation Investigation in Parkinson Patients: A PET Brain Imaging Study.J Imaging. 2022 Feb 25;8(3):56. doi: 10.3390/jimaging8030056. J Imaging. 2022. PMID: 35324611 Free PMC article.
-
Calabria as a Genetic Isolate: A Model for the Study of Neurodegenerative Diseases.Biomedicines. 2022 Sep 15;10(9):2288. doi: 10.3390/biomedicines10092288. Biomedicines. 2022. PMID: 36140389 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical